5 Results for "

Rezivertinib

" in MedChemExpress (MCE) Product Catalog:
Products (5)

5 Results for "Rezivertinib" in MCE Product Catalog:

1
1 Cited Publications
Cat. No.: HY-109189
CAS No.: 1835667-12-3
Purity:  99.62%
Synonyms: BPI-7711
Target:  

EGFR

Research Areas:  

Cancer

Rezivertinib (BPI-7711) is an orally active, highly selective and irreversible third-generation EGFR tyrosine kinase inhibitor (TKI). Rezivertinib exhibits high potency against the common activation EGFR and the resistance T790M mutations. Rezivertinib has excellent central nervous system (CNS) penetration and has antitumor activity .
loading...
    loading...
Cat. No.: HY-148053
CAS No.: 2227103-37-7
Purity:  99.68%
Target:  

Drug Metabolite

Research Areas:  

Cancer

Rezivertinib analogue 1 is a process impurity of osimertinib mesylate. Rezivertinib analogue 1 can be used in the study of non-small cell lung cancer .
loading...
    loading...
Cat. No.: HY-148053R
CAS No.: 2227103-37-7
Target:  

Drug Metabolite

Research Areas:  

Cancer

Rezivertinib analogue 1 (Standard) is the analytical standard of Rezivertinib analogue 1. This product is intended for research and analytical applications. Rezivertinib analogue 1 is a process impurity of osimertinib mesylate. Rezivertinib analogue 1 can be used in the study of non-small cell lung cancer[1].
loading...
    loading...
Cat. No.: HY-109189R
CAS No.: 1835667-12-3
Synonyms: BPI-7711 (Standard)
Research Areas:  

Cancer

Rezivertinib (Standard) is the analytical standard of Rezivertinib (HY-109189). This product is intended for research and analytical applications. Rezivertinib (BPI-7711) is an orally active, highly selective and irreversible third-generation EGFR tyrosine Kinase inhibitor (TKi). Rezivertinib exhibits high potency against the common activation EGFR and the resistance T790M mutations. Rezivertinib has excellent central nervous system (CNS) penetration and has antitumor activity .
loading...
    loading...
Cat. No.: HY-109189A
CAS No.: 2170255-78-2
Synonyms: BPI-7711 hydrochloride
Target:  

EGFR

Research Areas:  

Cancer

Rezivertinib (BPI-7711) hydrochloride is an orally active, highly selective and irreversible third-generation EGFR tyrosine kinase inhibitor (TKI). Rezivertinib hydrochloride exhibits high potency against the common activation EGFR and the resistance T790M mutations. Rezivertinib hydrochloride has excellent central nervous system (CNS) penetration and has antitumor activity, such as non-small cell lung cancer (NSCLC) .
loading...
    loading...